A California company is reviving a once abandoned treatment for Parkinson's disease. Erika Check assesses its odds of success.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Direct brain infusion of glial cell line derived neurotrophic factor in Parkinson disease
Related external links
Rights and permissions
About this article
Cite this article
Check, E. Second chance. Nat Med 13, 770–771 (2007). https://doi.org/10.1038/nm0707-770
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0707-770
This article is cited by
-
Absolute requirement of GDNF for adult catecholaminergic neuron survival
Nature Neuroscience (2008)
-
Positive clinical data in Parkinson's and ischemia buoy gene therapy
Nature Biotechnology (2007)